《肿瘤防治杂志》稿约

《肿瘤防治杂志》是经国家科学技术部和国家新闻出版署批准 ,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊 ,隶属于中华预防医学会系列杂志。本刊的办刊宗旨是 :以防为主 (三级预防 ) ,防治并举。办刊理念是 :传播肿瘤科学研究的信息 ,营造百家争鸣的学术氛围 ;科学为本的学术导向 ,质量至上的采编原则 ;成就作者 ,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版署列为“中国期刊方阵 (双效期刊 )” ,为中华预防医学会系列杂志优秀期刊…     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨是:以防为主(三级预防),防治并举。办刊理念是:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版署列为“中国期刊方阵(双效期刊)”,为中华预防医学会系列杂志优秀期刊。系中国…     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨是:以防为主(三级预防),防治并举。办刊理念是:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版署列为“中国期刊方阵(双效期刊)”,为中华预防医学会系列杂志优秀期刊。系中国生…     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨是:以防为主(三级预防),防治并举。办刊理念是:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版署列为“中国期刊方阵(双效期刊)”,为中华预防医学会系列杂志优秀期刊。系中国…     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨:以防为主(三级预防),防治并举。办刊理念:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版总署列为"中国期刊方阵(双效期刊)",为     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨:以防为主(三级预防),防治并举。办刊理念:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版总署列为"中国期刊方阵(双效期刊)",为     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准,由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊,隶属于中华预防医学会系列杂志。本刊的办刊宗旨:以防为主(三级预防),防治并举。办刊理念:传播肿瘤科学研究的信息,营造百家争鸣的学术氛围;科学为本的学术导向,质量至上的采编原则;成就作者,服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版总署列为"中国期刊方阵(双效期刊)",为     

《国际肿瘤学杂志》2017年征订启事

《国际肿瘤学杂志》（原刊名：国外医学肿瘤学分册）是由中华人民共和国国家卫生和计划生育委员会主管,中华医学会、山东省医学科学院主办的肿瘤专业学术性期刊,是中华医学会学系列杂志之一。主要报道国内外肿瘤学领域的新动态、新进展和新技术,反映国内外肿瘤学科临床、科研、防治工作的重大进展,促进国内外肿瘤学科学术交流。报道内容涵盖基础与临床、理论与技术各个方面,反映肿瘤学专业国际水平和发展趋势。为中国科技论文统计源期刊（中国科技核心期刊）。主要设置＂综述＂、＂论著＂、＂短篇论著＂、＂临床报道＂等栏目。适合广大肿瘤学及其相关学科的医疗、教学和科研工作者阅读和参考。     

三种肿瘤学期刊论著引文分析

引文指文后所附的参考文献,是知识交流和继承性的重要体现之一.文章的引文也是一篇完整的科学论文的重要组成部分,它不仅反应了作者吸收信息的能力,也是对其研究问题的深度和立论的可信度的支持.期刊的引文分析由此受到关注.<中华肿瘤杂志>、<癌症>、<肿瘤>为肿瘤学期刊中被引频次最高的[1].论著栏与其它栏目文献相比,是期刊与作者学术水平、技术水平的最佳表达.现就这三种期刊1998年的所有论著作一引文分析.以期从这一侧面了解肿瘤学期刊和肿瘤防治工作者的学术和技术水平.     

《中华肿瘤防治杂志》稿约

《中华肿瘤防治杂志》是经国家科学技术部和国家新闻出版总署批准，由中华人民共和国卫生部主管、中华预防医学会和山东省肿瘤防治研究院主办的肿瘤专业学术期刊，隶属于中华预防医学会系列杂志。本刊的办刊宗旨：以防为主（三级预防），防治并举。办刊理念：传播肿瘤科学研究的信息，营造百家争鸣的学术氛围；科学为本的学术导向，质量至上的采编原则；成就作者，服务读者。以从事肿瘤学基础理论研究、临床研究工作者及医学院校师生为主要读者对象。本刊被国家新闻出版署列为“中国期刊方阵（双效期刊）”，     

心理社会肿瘤学在中国的发展现状——机会与挑战

Objective: In China over the past decade, psychosocial oncology has emerged as a new program. Development of this program requires attention to current opportunities, obstacles and cultural concerns. Methods: A selected literature review of academic papers in Chinese and English language journals and web sites was analyzed for themes regarding the current status, challenges, and opportunities for psychosocial oncology in China. Results: China's national cancer strategy (2004-2010), based on WHO guidelines, is focused on cancer prevention and treatment, as well as quality of life among cancer patients and their families. The Chinese Anti-Cancer Association is now funding research, training and international collaboration in psychosocial oncology. The newly organized Chinese Psychosocial Oncology Society, founded in 2006, aims to provide a national forum for psychosocial oncology research. Cultural and systemic challenges to establishing psychosocial oncology as a core discipline in China include: (1) the family's desire to 'protect' cancer patients by with-holding cancer-related information; (2) stigma and privacy regarding mental health issues; (3) biomedical practitioners' claims that psychosocial on cology is not sufficiently evidence-based; and (4) limited funding for psychosocial oncology care and research. Conclusion:The International Psycho-Oncology Society (IPOS) is considered a valuable resource towards China's interest in partnering with the international psychosocial oncology community to enhance the discipline globally.     

乳腺肿瘤免疫治疗教学的探索与思考

肿瘤免疫治疗是通过增强自身免疫系统的力量去对抗肿瘤，已成为主要的肿瘤治疗模式。随着乳腺肿瘤发病率的不断上升以及临床肿瘤学的快速发展，这对专业的临床肿瘤学人才提出了更高的要求。免疫治疗为乳腺肿瘤治疗提供了广阔的空间，现有乳腺肿瘤学传统的教学模式存在诸多弊端，其教学改革已成为必然。本文旨在对乳腺肿瘤教学提出一些理论思考，同时也为乳腺肿瘤免疫治疗教学提供一些参考和建议。并试图探讨其重要性、方法和途径，以期帮助学生掌握基础理论和临床治疗方法，培养出更多乳腺肿瘤学的专业人才。     

Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs

Non‐clinical studies are necessary at each stage of the development of oncology drugs. Many experimental cancer models have been developed to investigate carcinogenesis, cancer progression, metastasis, and other aspects in cancer biology and these models turned out to be useful in the efficacy evaluation and the safety prediction of oncology drugs. While the diversity and the degree of engagement in genetic changes in the initiation of cancer cell growth and progression are widely accepted, it has become increasingly clear that the roles of host cells, tissue microenvironment, and the immune system also play important roles in cancer. Therefore, the methods used to develop oncology drugs should continuously be revised based on the advances in our understanding of cancer. In this review, we extensively summarize the effective use of those models, their advantages and disadvantages, ranges to be evaluated and limitations of the models currently used for the development and for the evaluation of oncology drugs.     

Psychosocial oncology in China

Objective  In China over the past decade, psychosocial oncology has emerged as a new program. Development of this program requires attention to current opportunities, obstacles and cultural concerns. Methods  A selected literature review of academic papers in Chinese and English language journals and web sites was analyzed for themes regarding the current status, challenges, and opportunities for psychosocial oncology in China. Results  China’s national cancer strategy (2004–2010), based on WHO guidelines, is focused on cancer prevention and treatment, as well as quality of life among cancer patients and their families. The Chinese Anti-Cancer Association is now funding research, training and international collaboration in psychosocial oncology. The newly organized Chinese Psychosocial Oncology Society, founded in 2006, aims to provide a national forum for psychosocial oncology research. Cultural and systemic challenges to establishing psychosocial oncology as a core discipline in China include: (1) the family’s desire to ‘protect’ cancer patients by with-holding cancer-related information; (2) stigma and privacy regarding mental health issues; (3) biomedical practitioners’ claims that psychosocial oncology is not sufficiently evidence-based; and (4) limited funding for psychosocial oncology care and research. Conclusion  The International Psycho-Oncology Society (IPOS) is considered a valuable resource towards China’s interest in partnering with the international psychosocial oncology community to enhance the discipline globally.     

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries. Medical oncology is a core member of the MDT and offers cancer patients a comprehensive and systemic approach to treatment and care, while ensuring evidence-based, safe and cost-effective use of cancer drugs and preserving the quality of life of cancer patients through the entire ‘cancer journey’. Medical oncologists are also engaged in clinical and translational research to promote innovation and new therapies and they contribute to cancer diagnosis, prevention and research, making a difference for patients in a dynamic, stimulating professional environment. Medical oncologists play an important role in shaping the future of healthcare through innovation and are also actively involved at the political level to ensure a maximum contribution of the profession to Society and to tackle future challenges. This position paper summarises the multifarious and vital contributions of medical oncology and medical oncologists to today's and tomorrow's professional cancer care.     

Multiple systems organ failure in the patient with cancer. Part II: nursing implications.

Because of the expansion of aggressive therapeutic modalities, multiple systems organ failure (MSOF)--a sequential deterioration in vital organ function, is being diagnosed with increasing frequency in today's cancer population. The high mortality rate associated with this complex syndrome demands that oncology nurses become knowledgeable about its potential for development. Part II of this two-part review focuses on the collaborative role of the nurse in the recognition and prevention of MSOF. Key criteria for determining systemic failure are described, and pertinent oncologic risk factors are identified. A clinical evaluation guideline outlines important assessment criteria, laboratory studies, and nursing priorities for each system.     

Exercise is medicine in oncology: Engaging clinicians to help patients move through cancer

Multiple organizations around the world have issued evidence-based exercise guidance for patients with cancer and cancer survivors. Recently, the American College of Sports Medicine has updated its exercise guidance for cancer prevention as well as for the prevention and treatment of a variety of cancer health-related outcomes (eg, fatigue, anxiety, depression, function, and quality of life). Despite these guidelines, the majority of people living with and beyond cancer are not regularly physically active. Among the reasons for this is a lack of clarity on the part of those who work in oncology clinical settings of their role in assessing, advising, and referring patients to exercise. The authors propose using the American College of Sports Medicine's Exercise Is Medicine initiative to address this practice gap. The simple proposal is for clinicians to assess, advise, and refer patients to either home-based or community-based exercise or for further evaluation and intervention in outpatient rehabilitation. To do this will require care coordination with appropriate professionals as well as change in the behaviors of clinicians, patients, and those who deliver the rehabilitation and exercise programming. Behavior change is one of many challenges to enacting the proposed practice changes. Other implementation challenges include capacity for triage and referral, the need for a program registry, costs and compensation, and workforce development. In conclusion, there is a call to action for key stakeholders to create the infrastructure and cultural adaptations needed so that all people living with and beyond cancer can be as active as is possible for them.     

中国胃癌放疗指南(2020版)

胃癌是我国高发的恶性肿瘤之一,且多数患者诊断时已处于进展期,放疗是多学科诊疗的重要组成部分。《中国胃癌放疗指南》由来自代表国内胃癌治疗领先水平的22家医院的放疗科、外科、内科、影像科的35位专家共同编写完成。作为中国首部胃癌放疗指南,将为我国胃癌放射治疗及综合治疗提供重要依据和参考,其在临床实践中的不断完善和更新,将会造福广大胃癌患者并促进学科的发展。     

The Harvard Joint Center for Radiation Therapy, 1968-1999: a unique concept and its relationship to the prevailing times in academic medicine

Purpose: Institutional structure, function, and philosophy reflect the organizational needs, and tend to mirror societal values of the times. For many years, the field of radiation oncology had among its major academic centers, an organization that served as a model for collaboration among health care institutions in an effort to serve the common good of its patients, hospitals, professional colleagues, and community. For over three decades, the Joint Center for Radiation Therapy (JCRT) was a leader in developing new organizational approaches for academic and clinical radiation oncology through the philosophy of collaboration in patient care, education, and research.

Methods and Results: In tracing the development and changes in organizational philosophy and structure of the JCRT, one can see the impact on academic oncology and cancer care through the emergence of both radiation and medical oncology as independent subspecialties, the importance of the National Cancer Act of 1971 accompanied by the growth of the NIH research and training programs and, more recently, the effect of the changing attitudes and approaches of hospitals, academicians, practitioners, and policy makers to health care delivery, structures, and cooperation.

Conclusion: Lessons learned from the 31-year history of the JCRT may help provide organizational insight useful in guiding academic oncology and academic medical centers through periods of change.     

从跟跑并跑到领跑:再论中国腹膜肿瘤学的建设发展与国际化历程

腹膜癌是癌症治疗历史上遗留的“老大难”问题，近40年来国际上致力于腹膜癌诊断治疗研究，取得了突破性进展，尤其是肿瘤细胞减灭术（cytoreductive surgery，CRS）加腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy，HIPEC）体系的形成和优化。近20年来，中国的腹膜癌研究进步迅速，在仪器设备研发、技术方案优化、人才队伍培养、学科组织建设等方面，均取得令人瞩目的成就，并快速融入腹膜肿瘤学国际联盟的国际化发展大格局。中国胃癌腹膜转移癌临床研究成果成为国际里程碑事件，C-HIPEC方案的推广实施，2021年国内主办第12届国际腹膜癌大会，都是该领域的突出成果，也使中国在腹膜癌诊治方面实现了从跟跑并跑到领跑的历史性转变。但是，与中国腹膜癌患者的巨大治疗需求相比，腹膜肿瘤学发展事业仍然任重而道远，需要全国肿瘤学家加倍努力，推动立足于国情的中国腹膜癌防治研究走向新高度。